clinical-trial is the sole category represented across all 1 tracked stories. Cognivia is most often covered alongside Dominique Demolle, which appears in 1 of these 1 story. Each carries 3 original sources on average. We currently track 1 Biotech story that mention Cognivia, all published on July 12, 2026.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Cognivia
clinical-trial is the sole category represented across all 1 tracked stories. Cognivia is most often covered alongside Dominique Demolle, which appears in 1 of these 1 story. Each carries 3 original sources on average. We currently track 1 Biotech story that mention Cognivia, all published on July 12, 2026.
Stories tracked
1
Sources per story
3
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 17 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Cognivia. Shared-story counts are live from our verified record — not editorial picks.
Cognivia and Mayo Clinic are zeroing in on non-adherence, missed appointments, and trial dropout—three behavioral factors that inflate clinical trial costs and delay drug development. By making patient behavior measurable, the partnership could help biopharma sponsors de-risk studies and improve real-world evidence.